How to Get Leqvio (Inclisiran) in Oregon

What Is Leqvio and Why Oregon Patients Are Seeking It

Leqvio is the brand name for inclisiran, a small interfering RNA (siRNA) that silences PCSK9 synthesis in hepatocytes, reducing LDL-cholesterol by roughly 50% with only two injections per year after the loading phase. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. The full prescribing information is available from the FDA [1].

Demand in Oregon has grown steadily because cardiologists serving the Portland, Eugene, and Bend corridors have adopted twice-yearly dosing as a practical alternative for patients with statin intolerance or persistent LDL-C elevation. Telehealth expansion following Oregon Senate Bill 1529 also opened access to patients in Klamath Falls, Medford, and rural eastern Oregon who previously had no local lipid specialist.

The ORION-10 trial (N=1,561, statin-treated ASCVD patients) showed inclisiran 284 mg reduced LDL-C by 52.3% from baseline at day 510 versus a 0.5% reduction with placebo (P<0.0001) [2]. The companion ORION-11 trial (N=1,617, HeFH or high cardiovascular risk) reported a 49.9% LDL-C reduction at day 510 (P<0.0001) [2]. Both trials were published in the New England Journal of Medicine in 2020 and form the principal evidence base cited in Oregon prescriber guidelines.

The American College of Cardiology's 2022 Expert Consensus Decision Pathway states: "PCSK9 inhibitors and inclisiran are recommended for patients with ASCVD or HeFH who require further LDL-C reduction despite maximally tolerated statin and ezetimibe therapy." [3]

Who Qualifies for Leqvio in Oregon

Patients who qualify generally fit two FDA-approved categories. First, adults with HeFH confirmed by clinical criteria (Simon Broome or Dutch Lipid Clinic Score) or genetic testing showing a pathogenic LDL receptor, ApoB, or PCSK9 variant. Second, adults with established ASCVD, meaning prior MI, stroke, peripheral artery disease, or coronary revascularization, whose LDL-C remains above goal on maximal statin plus ezetimibe.

Oregon Health Plan requires documentation of both the diagnosis and a failure to achieve target LDL-C on at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 90 days [4]. Patients with documented statin intolerance may substitute that requirement with evidence of a trial of at least two different statins.

A fasting lipid panel is the minimum lab requirement. Most Oregon prescribers also request a comprehensive metabolic panel to assess hepatic and renal baseline before the first injection [5]. The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease notes that LDL-C >190 mg/dL alone can justify PCSK9-pathway therapy without additional risk stratification [6].

Body weight, kidney function, and hepatic enzymes do not restrict dosing per the FDA label, but Oregon PA forms typically require the fasting LDL-C value and date of the qualifying lipid panel [1].

Labs Required Before Starting Leqvio in Oregon

A fasting lipid panel is the one non-negotiable prerequisite. Most Oregon plans and prescribers also collect a CMP (comprehensive metabolic panel) and, for HeFH patients, genetic confirmation or a documented Dutch Lipid Clinic Score.

Specifically, Oregon Health Plan's preferred drug list for cardiovascular agents requires [4]:

• Fasting LDL-C documented within the prior 12 months
• Documentation of current maximally tolerated statin dose and duration
• Diagnosis code for HeFH (E78.01) or ASCVD (I25.10, I63.x, I70.x, etc.)

Some commercial insurers operating in Oregon (Regence BlueCross BlueShield, Providence Health Plan, Moda Health) add a coronary artery calcium score or a 10-year ASCVD risk calculation using the Pooled Cohort Equations [6]. A lipid panel collected within the past 90 days carries the most weight during PA review. Older results extend the review timeline and may prompt a request for a repeat draw.

For telehealth patients, Oregon law permits laboratory orders placed by licensed out-of-state telehealth providers as long as the provider is registered with the Oregon Medical Board or the Oregon State Board of Nursing [7]. LabCorp and Quest Diagnostics have draw sites in Portland, Salem, Eugene, Medford, Bend, and Pendleton, making lab access feasible statewide.

Creatine kinase is not required by the Leqvio label but may be ordered if the patient reports myalgias from prior statin use, since statin myopathy history factors into the PA narrative [5].

How to Get a Leqvio Prescription in Oregon: Step-by-Step

Getting a prescription involves four sequential stages. Each stage has a defined timeline, and Oregon telehealth law allows each to happen remotely.

Stage 1: Initial Consultation (Week 1)

Schedule with a cardiologist, lipidologist, internal medicine physician, nurse practitioner, or physician assistant who holds an active Oregon prescribing license. Telehealth visits qualify. Bring or upload your most recent lipid panel, a medication history showing current statins or documentation of intolerance, and any prior cardiac records (catheterization reports, stress test results, echocardiograms).

Oregon's Prescription Drug Monitoring Program (PDMP) does not track inclisiran because it carries no abuse potential, so PDMP queries are not required before prescribing [8].

Stage 2: Lab Draw (Days 1 to 7)

Your provider orders a fasting lipid panel plus CMP. Results typically return within 24 to 72 hours through LabCorp or Quest. Telehealth providers may send the order to any Oregon-based draw site electronically.

Stage 3: Prior Authorization Submission (Days 5 to 14)

The prescriber's office submits the PA form to your insurer. Oregon Health Plan processes standard PA requests within 72 hours for non-urgent cases and within 24 hours for urgent requests per OAR 410-141-3895 [4]. Commercial plans vary: Regence typically processes in 5 to 10 business days, Moda in 3 to 7 business days.

The PA package must include the diagnosis code, fasting LDL-C value, documentation of prior statin therapy, and the prescriber's attestation that inclisiran is medically necessary. A letter of medical necessity drafted by the prescriber strengthens borderline cases, particularly when LDL-C is between 70 and 100 mg/dL on statin therapy [3].

Stage 4: Specialty Pharmacy and First Injection (Weeks 2 to 6)

Once approved, inclisiran is dispensed through a specialty pharmacy. Novartis's patient support program, Leqvio Together, connects patients to network specialty pharmacies and offers co-pay assistance that may reduce out-of-pocket cost to $0 for eligible commercially insured patients [1]. Oregon 503A compounding pharmacies may also compound and ship inclisiran injectables to patients within the state.

The first injection is administered subcutaneously by a healthcare provider. The second injection follows at month three. Every six months thereafter, one injection maintains the LDL-C reduction [2].

Telehealth Providers in Oregon Prescribing Leqvio

Oregon law explicitly authorizes telehealth prescribing of non-controlled medications including cardiovascular agents. Oregon Revised Statutes 677.097 and OAR 847-010-0057 permit prescribing after a synchronous audio-video visit that includes a clinical assessment, without requiring a prior in-person encounter [7].

Several national telehealth platforms have Oregon-licensed prescribers who handle lipid management. HealthRX connects Oregon patients to board-certified physicians and nurse practitioners who can order labs, submit PA documentation, and coordinate with specialty pharmacies, all within a single care pathway.

The table below summarizes the HealthRX Oregon Leqvio access pathway:

| Stage | Action | Typical Timeline | |---|---|---| | Consult | Telehealth visit, medication history review | Day 1 | | Labs | Fasting lipid panel, CMP ordered electronically | Days 1 to 3 | | PA | PA package submitted with diagnosis and labs | Days 5 to 14 | | Dispense | Specialty pharmacy ships to patient or provider | Days 14 to 35 | | Injection 1 | Subcutaneous injection at clinic or provider office | Day 1 of therapy | | Injection 2 | Three months after injection 1 | Month 3 | | Maintenance | Every 6 months | Ongoing |

Oregon's telehealth parity law (ORS 743A.058) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits, making the cost of an initial telehealth lipid consultation functionally equivalent to an office visit for most patients [9].

Prior Authorization Requirements in Oregon

Prior authorization is required for Leqvio on nearly every Oregon insurance plan. The exact documentation checklist varies by payer, but the core requirements are consistent across Oregon Health Plan, Regence, Providence, and Moda.

The American Heart Association's 2022 Secondary Prevention Guideline states: "For patients with ASCVD who are at very high risk and in whom LDL-C remains >70 mg/dL on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor or inclisiran is recommended (Class I, Level A evidence)." [10]

Oregon Health Plan PA criteria include [4]:

1. Confirmed HeFH or clinical ASCVD diagnosis with ICD-10 code
2. Fasting LDL-C >70 mg/dL on maximally tolerated statin (or documented intolerance)
3. Trial of ezetimibe 10 mg for at least 90 days or documented intolerance
4. Prescribing provider specialty (cardiology, endocrinology, or internal medicine preferred)
5. Attestation that brand-name inclisiran is medically necessary over generic alternatives (none currently exist)

Commercial plan denials can be appealed. Oregon law requires insurers to provide a written denial reason within the same timeframe as the initial PA decision [9]. A peer-to-peer review call between the prescriber and the plan's medical director resolves most first-level denials, particularly when the prescriber can reference the ORION-10/11 data showing 52% LDL-C reduction [2].

Patients on Medicare Part B should note that inclisiran, unlike most oral medications, may be covered under Part B as a physician-administered drug rather than Part D, depending on the administration setting. The Centers for Medicare and Medicaid Services issued guidance on PCSK9 inhibitor and inclisiran coverage under Part B in 2022 [11].

Leqvio Pharmacies in Oregon: Specialty and 503A Compounding

Leqvio is not stocked at retail pharmacies. It moves through specialty pharmacy channels because of its cold-chain storage requirements (refrigerated at 2 to 8°C) and the need for clinical coordination around injection scheduling.

Novartis's specialty pharmacy network includes Accredo, CVS Specialty, and Walgreens Specialty, each of which ships to Oregon addresses. Patients do not need to travel to a physical pharmacy location. The injectable is shipped to the patient's home or directly to the provider's clinic depending on the administration arrangement [1].

Oregon 503A compounding pharmacies licensed by the Oregon Board of Pharmacy may also compound and dispense inclisiran for individual patients under a valid prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act governs these pharmacies, and Oregon's Board of Pharmacy enforces compliance with USP <797> sterile compounding standards [12]. Compounded inclisiran may carry a lower acquisition cost for uninsured patients, but patients should verify that the compounding pharmacy holds active Oregon licensure and PCAB accreditation before use.

The FDA's 2024 guidance on 503A compounding notes that bulk drug substances used in compounding must appear on the FDA's 503A bulks list or meet the criteria under 21 U.S.C. 353a [12]. Patients and prescribers should confirm current status with the compounding pharmacy before ordering.

Transferring an Existing Leqvio Prescription to Oregon

Patients relocating to Oregon with an active Leqvio prescription from another state can transfer care without losing access. Oregon does not require a new PA application if the patient's prior insurer already approved inclisiran and the patient maintains the same insurance plan.

For patients switching to an Oregon-based insurer (Oregon Health Plan, a state exchange plan, or an employer plan using an Oregon carrier), a new PA submission is required because Oregon payers maintain independent formulary criteria [4]. The previous out-of-state prescriber's records, including lipid labs, PA approval letters, and injection logs, form the core documentation package for the new PA.

Oregon specialty pharmacies can receive prescription transfers from out-of-state specialty pharmacies for non-controlled medications. The receiving Oregon pharmacist will request the prescription from the originating pharmacy and coordinate with the new Oregon prescriber to update the prescription record [8]. This process generally takes 3 to 5 business days.

Patients in the middle of an injection cycle (for example, post-dose-2, awaiting the 6-month injection) should time their relocation to Oregon so the PA is in place before the next injection is due. A lapse of more than 10 weeks past the scheduled injection does not require restarting the loading dose sequence per Novartis's medical affairs guidance, but prescribers should review ORION trial data on dosing interval flexibility before extending beyond the standard 6-month window [2].

Side Effects, Safety, and Monitoring in Oregon

Inclisiran has a favorable safety profile in trials. Injection site reactions are the most common adverse event, occurring in 2.6% of inclisiran-treated patients versus 0.9% in the placebo group in the pooled ORION analysis [13]. Bronchitis was reported slightly more often in the inclisiran group (4.7% versus 3.7% placebo) in ORION-10 [2].

Liver enzyme elevations meeting Hy's Law criteria were not observed in either ORION-10 or ORION-11 [2]. Renal impairment does not require dose adjustment per the FDA label; pharmacokinetic data show no clinically significant change in inclisiran exposure across creatinine clearance categories [1].

Oregon prescribers typically schedule follow-up labs at 3 months (before dose 2) and at 12 months to confirm sustained LDL-C reduction. The ACC/AHA 2018 Cholesterol Guideline recommends a fasting lipid panel 4 to 12 weeks after starting a new lipid-lowering agent, then every 3 to 12 months as clinically indicated [14].

Pregnancy is a contraindication. Women of childbearing potential should use effective contraception during inclisiran therapy given the absence of adequate human pregnancy data [1]. Oregon telehealth providers follow ACOG guidance on contraception counseling when inclisiran is prescribed to premenopausal women [15].

Cost and Patient Assistance in Oregon

The list price of inclisiran is approximately $3,250 per injection in the United States as of 2024. With twice-yearly dosing, annual drug cost approaches $6,500 before insurance adjustments. Oregon Health Plan covers inclisiran with PA approval under its cardiovascular preferred drug list, bringing member cost-sharing to the standard OHP co-pay tier [4].

Commercially insured patients can access Novartis's Leqvio Together co-pay program, which may reduce out-of-pocket cost to $0 per injection for eligible patients [1]. Income-qualified uninsured patients may qualify for Novartis's patient assistance program, which provides inclisiran at no cost; enrollment is managed through the Leqvio Together portal.

Medicare Part B beneficiaries receiving inclisiran in a physician's office or clinic may have 80% of the Medicare-approved amount covered after the Part B deductible, with the remaining 20% subject to supplemental or Medigap coverage [11].